OA10151A - Method of administering azithromycin - Google Patents

Method of administering azithromycin Download PDF

Info

Publication number
OA10151A
OA10151A OA60654A OA60654A OA10151A OA 10151 A OA10151 A OA 10151A OA 60654 A OA60654 A OA 60654A OA 60654 A OA60654 A OA 60654A OA 10151 A OA10151 A OA 10151A
Authority
OA
OAPI
Prior art keywords
azithromycin
dosage form
food
exhibit
suspension
Prior art date
Application number
OA60654A
Other languages
English (en)
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of OA10151A publication Critical patent/OA10151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
OA60654A 1994-04-29 1995-04-28 Method of administering azithromycin OA10151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
OA10151A true OA10151A (en) 1996-12-18

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60654A OA10151A (en) 1994-04-29 1995-04-28 Method of administering azithromycin

Country Status (31)

Country Link
US (2) US5605889A (fr)
EP (1) EP0679400B1 (fr)
JP (3) JPH07300420A (fr)
KR (1) KR100354310B1 (fr)
CN (1) CN1088362C (fr)
AP (1) AP566A (fr)
AT (1) ATE183395T1 (fr)
AU (1) AU709328B2 (fr)
CA (1) CA2148071C (fr)
CO (1) CO4560547A1 (fr)
DE (1) DE69511451T2 (fr)
DK (1) DK0679400T3 (fr)
DZ (1) DZ1877A1 (fr)
ES (1) ES2136247T3 (fr)
FI (1) FI952060A7 (fr)
GR (1) GR3031290T3 (fr)
HU (1) HUT75244A (fr)
IL (1) IL113437A (fr)
LV (1) LV10918B (fr)
MA (1) MA23533A1 (fr)
NO (1) NO314386B1 (fr)
NZ (1) NZ548384A (fr)
OA (1) OA10151A (fr)
RU (1) RU2128998C1 (fr)
SI (1) SI0679400T1 (fr)
TN (1) TNSN95046A1 (fr)
TW (1) TW499311B (fr)
UA (1) UA34464C2 (fr)
UY (1) UY23935A1 (fr)
YU (1) YU49483B (fr)
ZA (1) ZA953439B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0758244B2 (fr) † 1994-05-06 2008-02-13 Pfizer Inc. Formes galeniques a liberation controlee de l'azithromycine
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
DK0801559T3 (da) * 1995-02-08 2002-06-17 Yamanouchi Europ Bv Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
HUP0100433A3 (en) * 1997-12-22 2003-01-28 Schering Corp Orally administrable solid ribavirin dosage forms and process for producing them
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
PL198797B1 (pl) * 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
ATE320441T1 (de) * 2000-07-25 2006-04-15 Silanes Sa De Cv Lab Einstufiges verfahren zur herstellung von 7,16-
DE60114028T2 (de) 2000-08-23 2006-07-13 Wockhardt Ltd. Verfahren zur herstellung von wasserfreiem azithromycin
AU2002232406C1 (en) * 2000-11-06 2009-03-05 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
EP1344527B1 (fr) * 2000-11-15 2009-09-09 Masao Sugamata Antibiotiques macrolides pour le traitement de l'endometriose ou du myome uterin
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
IL158591A0 (en) * 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
EP1671979B1 (fr) 2001-05-22 2008-08-13 Pfizer Products Inc. Nouvelle forme cristalline de l'azithromycine
HRP20040163A2 (en) * 2001-08-21 2005-02-28 Pfizer Products Inc. Single dose azithromycin for treating respiratory infections
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
US20040226852A1 (en) * 2003-02-19 2004-11-18 Michael Pesachovich Method of stabilizing azithromycin
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
EP1541134A3 (fr) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Compositions stabilisées de azithromycin
US6764997B2 (en) * 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
IL161996A0 (en) * 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
EP1455757A2 (fr) * 2001-12-21 2004-09-15 Pfizer Products Inc. Procedes de granulation par voie humide d'azithromycine
JP2006501137A (ja) * 2002-01-16 2006-01-12 ペプジェン コーポレイション インターフェロン−τの経口投与
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
AU2003209475A1 (en) * 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
AU2004238253B2 (en) * 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2005009447A1 (fr) * 2003-07-24 2005-02-03 Pliva - Research And Development Ltd. Dose unique a dissolution rapide d'azithromycine
AR045142A1 (es) * 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
WO2005021056A1 (fr) * 2003-08-21 2005-03-10 Cns, Inc. Systeme de distribution de materiau effervescent
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
JP2007513143A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
CA2549225A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions medicamenteuses cristallines multiparticulaires contenant de preference un poloxamere et un glyceride
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
CA2547239A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes posologiques multiparticulaires d'azithromycine obtenues par des procedes se deroulant en milieu liquide
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
EP1699398A4 (fr) * 2003-12-30 2007-10-17 3M Innovative Properties Co Amelioration de la reponse immunitaire
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
ES2294979T1 (es) * 2005-01-27 2008-04-16 Alembic Limited Formulacion de levetiracetam de liberacion prolongada.
EP1855693B1 (fr) * 2005-03-07 2009-07-29 Teva Pharmaceutical Industries Ltd. Poudre d'azithromycine pour compositions orales sous forme de suspensions
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
DK1884242T3 (da) 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
KR20130016386A (ko) * 2005-08-10 2013-02-14 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
GB0618966D0 (en) * 2006-09-26 2006-11-08 Iti Scotland Ltd Cartridge system
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011122524A1 (fr) 2010-03-29 2011-10-06 アステラス製薬株式会社 Composition pharmaceutique à libération contrôlée
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
CN104168900A (zh) 2012-02-06 2014-11-26 梅里亚有限公司 包含全身性地起作用的活性剂的杀寄生虫口服兽用组合物、方法及其用途
IN2014MN01706A (fr) 2012-02-28 2015-05-29 Seoul Pharma Co Ltd
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
WO2015070131A1 (fr) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Limited Compositions et méthodes de traitement à base de disodium de fosfomycine
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (fr) * 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
CA2094060A1 (fr) * 1990-10-15 1992-04-16 Toshifumi Asaka Erythromycine modifiee en position 2' ou derives
TW271400B (fr) 1992-07-30 1996-03-01 Pfizer
EP0721324A1 (fr) 1993-10-01 1996-07-17 The Procter & Gamble Company Utilisation de l'azithromycine pour le traitement de la parodontite de l'adulte
EP0758244B2 (fr) 1994-05-06 2008-02-13 Pfizer Inc. Formes galeniques a liberation controlee de l'azithromycine

Also Published As

Publication number Publication date
AP9500728A0 (en) 1995-04-30
FI952060L (fi) 1995-10-30
DK0679400T3 (da) 1999-12-06
LV10918A (lv) 1995-12-20
JPH07300420A (ja) 1995-11-14
KR950028764A (ko) 1995-11-22
CO4560547A1 (es) 1998-02-10
LV10918B (en) 1996-06-20
TW499311B (en) 2002-08-21
FI952060A7 (fi) 1995-10-30
KR100354310B1 (ko) 2002-12-26
AP566A (en) 1996-11-22
USRE39149E1 (en) 2006-06-27
DE69511451T2 (de) 1999-12-09
DE69511451D1 (de) 1999-09-23
NZ548384A (en) 2008-04-30
SI0679400T1 (en) 1999-10-31
MA23533A1 (fr) 1995-12-31
CA2148071C (fr) 2000-10-17
HU9501206D0 (en) 1995-06-28
EP0679400A1 (fr) 1995-11-02
UY23935A1 (es) 1995-09-12
DZ1877A1 (fr) 2002-02-17
US5605889A (en) 1997-02-25
NO951630L (no) 1995-10-30
ZA953439B (en) 1996-10-28
ATE183395T1 (de) 1999-09-15
AU1771195A (en) 1995-11-09
JP2008231120A (ja) 2008-10-02
NO951630D0 (no) 1995-04-28
IL113437A (en) 2001-04-30
RU2128998C1 (ru) 1999-04-20
YU27195A (sh) 1999-03-04
FI952060A0 (fi) 1995-04-28
CN1088362C (zh) 2002-07-31
ES2136247T3 (es) 1999-11-16
CA2148071A1 (fr) 1995-10-30
CN1114879A (zh) 1996-01-17
EP0679400B1 (fr) 1999-08-18
AU709328B2 (en) 1999-08-26
TNSN95046A1 (fr) 1996-02-06
NO314386B1 (no) 2003-03-17
JP2005015466A (ja) 2005-01-20
GR3031290T3 (en) 1999-12-31
YU49483B (sh) 2006-08-17
UA34464C2 (uk) 2001-03-15
RU95106639A (ru) 1997-01-20
IL113437A0 (en) 1995-07-31
HUT75244A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
US5605889A (en) Method of administering azithromycin
FI90393B (fi) Menetelmä oraalisen, farmaseuttisen valmisteen valmistamiseksi, joka on pysyvä värin muuttumista vastaan
US4321253A (en) Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
KR100493836B1 (ko) 옥스카르바제핀을 포함하는 제약 조성물
US4587118A (en) Dry sustained release theophylline oral formulation
KR960011772B1 (ko) 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제
EP2544660B1 (fr) Suspension de rifaximine prête à l'emploi
PT582396E (pt) Composicoes para mascarar o gosto amargo de agentes farmaceuticos
CZ332598A3 (cs) Pevná dávková forma cisapridu
JP2007532416A (ja) 液状の配合物を調合するための容器
AU744318B2 (en) Method of administering azithromycin
EP1610764A1 (fr) Excipient de masquage de gout pour des particules d'oxazolidinone enrobees
MXPA05000301A (es) Formas de dosificacion liquida de inhibidores de bomba de proton.
EP0835654A1 (fr) Préparations pharmaceutiques pour administration orale à libération contrÔlée contenant du glucomannan
KR20000050265A (ko) 아지스로마이신 경구 투여 제형을 포함하는 치료용 패키지